What non‑stimulant medications can be used to treat ADHD in a patient who also has anxiety?

Non-Stimulant Medications for ADHD with Comorbid Anxiety

Atomoxetine is the optimal first-line non-stimulant medication for patients with ADHD and comorbid anxiety, as it effectively treats both conditions simultaneously while avoiding the anxiety-exacerbating effects of stimulants. 1

Primary Recommendation: Atomoxetine

Atomoxetine should be initiated as the primary non-stimulant choice because it addresses both ADHD symptoms and anxiety through its norepinephrine reuptake inhibition mechanism. 2, 1

Key Advantages for Anxiety Comorbidity

• Clinical evidence demonstrates atomoxetine's efficacy in treating ADHD when anxiety is present, with research showing superior anxiety reduction compared to methylphenidate starting at week 4 of treatment. 1, 3
• Provides continuous 24-hour symptom coverage without rebound effects that could worsen anxiety symptoms, unlike stimulants which may cause end-of-dose anxiety spikes. 2, 1
• Does not carry the anxiety-exacerbating risks associated with stimulant medications, making it safer for patients with baseline anxiety disorders. 1, 4

Practical Dosing Strategy

• Start at 0.5 mg/kg/day and titrate to 1.2 mg/kg/day over several weeks. 1
• Can be dosed once daily (preferably evening) or split into morning and evening doses to minimize side effects like nausea. 2, 1
• Counsel patients that full therapeutic effect requires 6–12 weeks—this is critical to prevent premature discontinuation. 2, 1

Monitoring Requirements

• Assess for suicidality at each visit (FDA black-box warning, though rare in practice). 2, 1
• Monitor pulse and blood pressure, though cardiovascular effects are minimal compared to stimulants. 2, 1
• Track clinical worsening or mood changes during the initial titration period. 2, 1

Alternative Non-Stimulant: Guanfacine Extended-Release

Guanfacine ER is the preferred alternative when atomoxetine is not tolerated or when additional blood pressure concerns exist, as it can actually lower blood pressure while treating ADHD and anxiety. 1

When to Choose Guanfacine

• Evidence demonstrates benefit for comorbid anxiety in ADHD patients, making it a viable second option. 1
• Particularly useful if the patient has elevated blood pressure (≥130/85 mmHg), as hypotension is a potential side effect that becomes therapeutic in this context. 1
• Consider as first-line adjunct when sleep disorders coexist with ADHD and anxiety. 2

Dosing and Administration

• Start at 0.1 mg/kg once daily, adjusted for body weight. 2, 1
• Administer in the evening to mitigate sedation, which is a common side effect. 2, 1
• Therapeutic effect typically appears within 2–4 weeks, faster than atomoxetine but slower than stimulants. 2, 1

Critical Safety Considerations

• Monitor for hypotension, bradycardia, and excessive sedation at every visit during titration. 2, 1
• Never abruptly discontinue—taper gradually to prevent rebound hypertension, which can be severe. 2, 1

Third Option: Clonidine Extended-Release

Clonidine ER shares similar properties with guanfacine but requires twice-daily dosing, making it less convenient but still effective for ADHD with anxiety. 2, 1

• May be particularly useful when sleep disturbances coexist with ADHD and anxiety symptoms. 1
• Shares the blood pressure-lowering profile of guanfacine, beneficial in patients with elevated BP. 1
• Requires twice-daily administration, which may reduce adherence compared to once-daily guanfacine. 2, 1

Treatment Algorithm for ADHD with Anxiety

1. Initiate atomoxetine at 0.5 mg/kg/day, titrating to 1.2 mg/kg/day over 2–4 weeks. 1
2. Counsel patient about 6–12 week timeline for full effect to maintain adherence. 2, 1
3. If atomoxetine is not tolerated or partially effective after 12 weeks, switch to guanfacine ER at 0.1 mg/kg once daily in the evening. 2, 1
4. Consider clonidine ER if sleep disturbances are prominent and guanfacine is not suitable. 1
5. If anxiety remains inadequately controlled despite ADHD improvement, add cognitive-behavioral therapy or consider selective serotonin reuptake inhibitors (SSRIs) as adjunctive treatment. 4

Important Clinical Pitfalls

Stimulant Considerations

• While stimulants remain first-line for ADHD in general, they may exacerbate anxiety symptoms in patients with comorbid anxiety disorders. 1, 4
• Research shows that stimulants often improve both ADHD and anxiety symptoms in many patients, but this is unpredictable and individual response varies. 4
• Stimulants should only be reconsidered after anxiety is well-controlled through non-stimulant therapy or other interventions. 1

Timing Expectations

• Do not expect rapid response with atomoxetine—unlike stimulants which work within hours, atomoxetine requires patience. 2, 1
• Premature discontinuation due to delayed onset is a common error—reinforce the 6–12 week timeline repeatedly. 2, 1

Cardiovascular Monitoring

• Obtain baseline blood pressure, pulse, and cardiac history before initiating any ADHD medication, even non-stimulants. 1
• Alpha-2 agonists (guanfacine, clonidine) can cause clinically significant hypotension and bradycardia, requiring regular monitoring. 2, 1

Adjunctive Treatment Strategies

Cognitive-behavioral therapy (CBT) targeting anxiety is strongly recommended and considered superior to medication alone for managing comorbid anxiety in ADHD patients. 4

• Psychoeducation about both conditions should be integrated into the treatment plan from the outset. 2
• If moderate to severe anxiety persists despite adequate ADHD treatment with non-stimulants, SSRIs can be added with appropriate caution. 4
• Viloxazine extended-release is another norepinephrine reuptake inhibitor that may be considered, though evidence is more limited than for atomoxetine. 5, 6